activ
immun
elicit
last
immun
respons
bodi
passiv
immunotherapi
transient
equip
bodi
exogen
gener
immunolog
effector
form
either
targetspecif
antibodi
lymphocyt
function
targetspecif
receptor
either
case
administr
express
recombin
protein
play
fundament
role
mrna
prepar
vitro
transcript
ivt
increasingli
appreci
drug
substanc
deliveri
recombin
protein
biolog
role
transient
carrier
genet
inform
translat
protein
cytoplasm
therapeut
applic
mrna
combin
sever
advantag
exampl
compar
transfect
dna
mrna
harbor
inher
safeti
featur
associ
risk
induc
genom
chang
potenti
advers
effect
temporari
due
transient
natur
compar
administr
recombin
protein
produc
bioreactor
mrna
allow
suppli
protein
difficult
manufactur
offer
extend
pharmacokinet
shortliv
protein
base
great
progress
understand
manipul
mrna
properti
efficaci
data
variou
model
demonstr
ivt
mrna
constitut
potent
flexibl
platform
technolog
start
introduct
passiv
immunotherapi
review
summar
current
statu
ivt
mrna
technolog
applic
immunolog
intervent
bodi
continu
expos
molecul
may
indic
diseas
parasit
invas
immun
system
respons
detect
clearanc
molecul
control
underli
caus
immedi
discrimin
self
foreign
upon
first
exposur
mediat
innat
immun
signal
induc
innat
immun
call
pathogenassoci
damageassoci
molecular
pattern
pamp
damp
innat
immun
system
character
induct
gener
defens
broad
spectrum
infecti
agent
mainli
aim
clearanc
tissu
damag
site
infect
interrupt
pathogen
replic
respons
specif
target
follow
prolong
repeat
exposur
process
adapt
immun
system
import
effector
adapt
immun
highli
special
cell
b
cell
secret
antibodi
solubl
cellassoci
antigen
cytotox
cell
ctl
recogn
kill
infect
neoplast
cell
regulatori
cell
augment
b
cell
matur
inhibit
autoreact
immun
cell
dendrit
cell
dc
process
present
antigen
transit
innat
adapt
immun
b
cell
progress
toward
persist
memori
cell
react
faster
greater
affin
foreign
molecul
upon
reexposur
compar
innat
immun
adapt
immun
usual
requir
week
oppos
minut
effect
respons
novel
target
achiev
advantag
adapt
immun
system
includ
abil
launch
specif
immun
respons
also
antigen
endogen
microbi
origin
may
associ
degen
neoplast
diseas
manipul
immun
system
import
compon
mani
prophylact
therapeut
applic
infecti
degen
neoplast
diseas
divers
repertoir
method
roughli
divid
four
approach
activ
immun
vaccin
prepar
adapt
memori
respons
usual
prior
first
exposur
constitut
one
efficaci
costeffect
medic
intervent
immun
antigen
gener
lead
induct
antibodi
product
wherea
instanc
inocul
attenu
virus
also
elicit
cytotox
effector
cell
addit
activ
immun
accomplish
adopt
cell
transfer
typic
set
dendrit
cell
load
tumor
antigen
ex
vivo
subsequ
infus
patient
induc
adopt
immun
respons
cancer
cell
contrast
passiv
immunotherapi
circumv
initi
step
requir
immun
respons
launch
direct
immun
system
effici
desir
medic
target
cellular
approach
ctl
equip
recombin
receptor
ex
vivo
cell
design
attack
neoplast
cell
express
cognat
tumorassoci
antigen
immedi
infus
passiv
immun
administr
process
antibodi
deriv
human
anim
donor
wellestablish
emerg
procedur
treatment
snakebit
envenom
post
exposur
prophylaxi
exampl
rabi
advantag
passiv
immun
protect
antibodi
provid
short
time
applic
recombin
antibodi
expand
number
avail
target
increasingli
import
augment
convent
therapi
cancer
passiv
immunotherapi
either
requir
exploit
modern
nucleic
acidbas
method
among
mrna
latest
technolog
present
review
dedic
provid
overview
mrna
passiv
immunotherapi
introduc
immunolog
approach
well
mrna
technolog
well
known
protect
rais
today
licens
vaccin
primarili
antibodydepend
fig
basic
explain
long
success
histori
passiv
immunotherapi
fig
protect
capac
serum
bacteri
toxin
discov
earli
avoid
control
infect
passiv
immun
base
transfer
serum
later
polyclon
immun
globulin
antibodi
prepar
convalesc
vaccin
human
anim
prior
discoveri
antibiot
serum
antidot
bacteri
diseas
thu
follow
success
passiv
immun
diphtheria
toxin
whole
plethora
serum
immun
globulin
therapi
viral
bacteri
diseas
well
neutral
snake
toxin
develop
clinic
benefit
serum
immun
globulin
therapi
demonstr
viral
diseas
influenza
measl
polio
bacteri
infect
meningococcu
pneumococcu
advent
antibiot
use
serum
polyclon
immun
globulin
prepar
antibacteri
agent
larg
discontinu
late
howev
therapi
retain
nich
treatment
venom
toxin
certain
viral
infect
second
half
twentieth
centuri
polyclon
antibodi
prepar
develop
part
licens
prophylaxi
treatment
hepat
b
cytomegaloviru
varicellazost
viru
vaccinia
viru
rabi
respiratori
syncyti
viru
west
nile
viru
variou
hemorrhag
fever
instanc
passiv
immun
argentin
hemorrhag
fever
show
benefici
effect
appli
within
week
emerg
symptom
postexposur
treatment
human
equin
immunoglobulin
recommend
rabi
moreov
botul
treat
equin
antitoxin
immun
globulin
prepar
nonhuman
origin
particularli
prone
elicit
immun
respons
obstruct
therapeut
use
efficaci
disadvantag
difficulti
associ
use
serum
polyclon
globulin
prepar
often
high
content
nonneutr
antibodi
batchtobatch
variat
case
human
sourc
avail
appropri
immun
donor
groundbreak
work
describ
product
monoclon
antibodi
mab
immort
b
cell
result
hybridoma
technolog
rapidli
exploit
clinic
use
instanc
produc
mab
prevent
organ
reject
recombin
technolog
expand
avail
therapi
base
mab
vitro
antibodi
select
technolog
like
phage
ribosom
display
develop
enabl
gener
highli
specif
human
mab
librari
may
even
specif
antigen
schemat
illustr
compar
activ
immun
passiv
antibodi
immunotherapi
activ
immun
trigger
natur
infect
vaccin
antigen
pattern
present
antigenpres
cell
lymph
node
lead
cell
mediat
activ
antigenspecif
b
cell
consequ
b
lymphocyt
differenti
plasma
cell
produc
secret
antigenspecif
antibodi
bind
cognat
structur
final
lead
clearanc
b
instead
produc
plasma
b
cell
antibodi
manufactur
recombinantli
administ
instanc
subcutan
inject
passiv
immun
inject
antibodi
enter
circul
diffus
act
like
endogen
antibodi
c
dnabas
passiv
immun
dna
often
packag
nanoparticl
eg
viru
capsid
instanc
inject
intramuscularli
uptak
muscl
cell
dna
releas
cytosol
transcript
mrna
dna
enter
cell
nucleu
first
mrna
translat
antibodi
secret
bind
cognat
target
high
throughput
techniqu
amplifi
clone
antibodi
gene
singl
human
b
cell
describ
although
recombin
mab
technolog
exploit
larg
varieti
differ
antibodi
format
fig
preval
type
still
fullsiz
antibodi
igg
class
addit
variabl
domain
essenti
antigen
bind
contain
constant
domain
includ
fcregion
latter
import
antibodi
function
mediat
antibodydepend
cellular
cytotox
adcc
complementdepend
cytotox
cdc
antibodydepend
cellular
phagocytosi
adcp
furthermor
bind
neonat
fc
receptor
fcrn
play
role
control
antibodi
halflif
day
human
igg
fcrn
rescu
bound
antibodi
degrad
transport
back
cell
surfac
releas
extracellular
space
specif
mutat
fc
region
increas
affin
fcrn
shown
prolong
antibodi
halflif
fivefold
addit
impact
fcrn
bind
halflif
also
benefit
larg
size
igg
obstruct
antibodi
clearanc
kidney
well
metabol
cytochrom
downsid
larg
size
correspondingli
low
access
penetr
tissu
affect
therapeut
efficaci
fullsiz
antibodi
often
posttransl
glycosyl
modul
fc
function
although
aglycosyl
igg
produc
bacteria
modern
product
process
usual
take
advantag
cellular
machineri
advanc
posttransl
matur
secret
eukaryot
cell
vast
major
approv
therapeut
antibodi
current
produc
mammalian
cell
product
process
optim
especi
predomin
product
system
continu
chines
hamster
ovari
cho
cell
line
cho
cell
secret
antibodi
neglig
nonhuman
glycoform
also
amen
glycoengin
differ
glycoform
depend
product
system
affect
distribut
stabil
antibodi
fc
effector
function
immunogen
recipi
sinc
tradit
express
host
e
coli
allow
effici
product
fullsiz
antibodi
smaller
protein
consist
fragment
deriv
variabl
domain
develop
promis
altern
singlechain
variabl
fragment
scfv
variou
deriv
thereof
preserv
antigen
bind
facilit
manufactur
fig
c
anoth
type
antibodi
fragment
deriv
camelid
cartilagin
fish
anim
produc
singledomain
antibodi
devoid
light
chain
fig
sinc
antigen
recogn
heavychainonli
v
h
domain
v
h
h
camelid
variabl
v
h
h
fragment
easili
engin
nanobodi
offer
addit
advantag
improv
heat
ph
stabil
moreov
also
assembl
v
h
hbase
neutral
agent
vna
fig
variou
studi
demonstr
multival
format
effect
monoval
singledomain
antibodi
notabl
format
base
antibodi
fragment
rel
effici
produc
less
expens
bacteri
express
system
typic
employ
e
coli
antibodi
fragment
produc
system
often
target
oxid
environ
periplasm
use
specif
signal
peptid
foster
disulfid
bond
format
proper
fold
moreov
enhanc
express
chaperon
cytoplasm
oxidas
demonstr
increas
yield
antibodi
fragment
small
antibodi
fragment
also
basi
develop
concept
bispecif
antibodi
year
ago
initi
singl
chain
antibodi
differ
bind
specif
fuse
ctermin
end
heavi
chain
igg
gener
first
bispecif
igg
molecul
benefit
knobintohol
technolog
today
mani
differ
bispecif
antibodi
format
combin
two
differ
antigen
bind
domain
one
molecul
avail
fig
among
bispecif
diabodi
bi
scfv
bite
antibodi
promin
exampl
gener
bispecif
antibodi
deploy
target
therapeut
substanc
toxin
radionuclid
drug
well
effector
cell
like
ctl
site
cognat
antigen
express
associ
small
size
mani
format
use
antibodi
fragment
clear
renal
elimin
moreov
absenc
fc
region
recycl
fcrn
rescu
mechan
take
place
consequ
format
usual
reveal
short
plasma
halfliv
instanc
bi
scfv
antibodi
serum
halflif
less
h
usual
requir
continu
infus
case
bite
blinatumomab
antibodi
usual
administ
daili
due
short
halflif
possibl
strategi
extend
serum
halfliv
sitespecif
pegyl
fusion
fc
region
howev
latter
approach
would
negat
variou
advantag
antibodi
fragment
includ
better
faster
tissu
penetr
shown
small
singledomain
antibodi
could
even
cross
bloodbrain
barrier
case
antirabi
antibodi
allow
partial
rescu
mice
challeng
viru
inject
brain
contrast
fullsiz
immunoglobulin
today
monoclon
antibodi
play
import
role
therapeut
armamentarium
dozen
antibodi
licens
treat
cancer
rheumatoid
arthriti
multipl
sclerosi
psoriasi
allergi
system
lupu
diseas
addit
mab
shown
promis
protect
variou
microorgan
virus
fungal
infect
well
treat
neurodegen
diseas
howev
mab
infecti
diseas
indic
still
scarc
among
licens
product
palivizumab
respiratori
syncyti
viru
prophylaxi
highrisk
infant
first
antivir
mab
approv
fda
sinc
antibodi
anthrax
rabi
india
becam
avail
addit
bezlotoxumab
bind
clostridium
difficil
toxin
use
prevent
recurr
bacteri
infect
mab
treat
cancer
still
largest
group
licens
product
rituximab
direct
transmembran
protein
surfac
b
lymphocyt
first
mab
clinic
use
howev
mani
mab
antitumor
therapi
high
dose
need
obtain
clinic
efficaci
success
exampl
bispecif
antibodi
firstinclass
bite
blinatumomab
approv
treatment
acut
lymphoblast
leukemia
addit
administr
immunoglobulin
passiv
immun
also
confer
transfer
function
immun
cell
adopt
transfer
ctl
shown
potent
therapeut
mean
treat
viral
infect
cancer
end
cell
equip
addit
tcell
receptor
tcr
chimer
antigen
receptor
car
car
limit
bind
surfac
antigen
tcr
recogn
mhcpresent
peptid
deriv
also
intracellular
protein
first
success
clinic
trial
engin
tcr
ctl
demonstr
tumor
regress
report
subsequ
passiv
immunotherapi
tcrengin
cell
becam
import
approach
antitumor
treatment
effici
target
kill
cancer
cell
express
respect
antigen
patient
variou
form
cancer
includ
metastat
melanoma
synovi
sarcoma
colorect
carcinoma
demonstr
possibl
problem
specif
use
tcrengin
cell
presenc
endogen
tcr
mispair
endogen
introduc
may
creat
new
specif
potenti
reactiv
host
molecul
avoid
mispair
use
cell
suggest
sinc
pair
altern
gene
edit
explor
disabl
endogen
tcr
express
concept
car
develop
refin
use
scfv
fragment
obtain
antibodylik
receptor
specif
without
need
transfer
multipl
gene
first
gener
car
consist
antigenspecif
scfv
fuse
transmembran
intracellular
tcr
signal
domain
confer
transient
activ
cytotox
cell
upon
target
bind
scfv
domain
engin
cell
activ
mhcindepend
manner
subsequ
gener
car
improv
respect
cytotox
persist
includ
addit
costimulatori
domain
cell
engin
car
target
specif
tumor
antigen
remark
success
treat
hematolog
malign
like
leukemia
lymphoma
instanc
car
cell
repeatedli
reveal
complet
durabl
remiss
patient
bcell
acut
lymphoblast
leukemia
ball
contrast
car
cell
therapi
face
variou
challeng
solid
tumor
present
common
techniqu
gener
tcror
carengin
cell
util
viral
gene
transduct
retroor
lentivir
vector
howev
perman
express
transgen
receptor
mediat
effici
technolog
disadvantag
case
therapyrel
sever
toxic
due
accident
cross
reactiv
ontargetofftissu
offtarget
toxic
engin
lymphocyt
attack
healthi
host
cell
well
cytokin
releas
syndrom
fear
sideeffect
repeatedli
report
viru
vector
transduc
cell
appli
anoth
concern
use
retrovir
vector
potenti
induc
insert
mutagenesi
genotox
effector
cell
henc
precis
cell
manipul
current
investig
among
gene
edit
primari
human
cell
recent
demonstr
effici
approach
cell
engin
adopt
transfer
inevit
requir
use
nucleic
acid
encod
targetspecif
receptor
antibodi
immunotherapi
deploy
recombin
protein
howev
point
maintain
therapeut
effect
level
may
requir
frequent
administr
depend
clearanc
indic
thu
dnamedi
antibodi
express
directli
bodi
may
repres
attract
altern
administr
recombin
protein
fig
plasmid
well
viral
vector
use
passiv
immun
although
effici
small
anim
model
strong
express
recombin
gene
use
unformul
dna
scale
well
larger
anim
includ
primat
consequ
applic
recombin
adenoassoci
virus
aav
current
prefer
method
transduct
antibodi
gene
interest
earli
work
reach
singl
digit
serum
titer
later
studi
advanc
vector
design
report
express
level
high
even
singl
digit
mgml
rang
much
work
done
field
hiv
prophylaxi
singl
intramuscular
inject
recombin
aav
demonstr
elicit
peak
antibodi
titer
mice
treat
mice
reveal
substanti
antihiv
antibodi
level
year
protect
challeng
although
aav
usual
maintain
episom
state
vector
still
harbor
inher
risk
insert
mutagenesi
patient
hepatocellular
carcinoma
integr
known
cancer
gene
observ
moreov
aavbas
immunotherapi
face
variou
issu
regard
immunogen
substanti
percentag
popul
alreadi
contact
use
viru
consequ
show
preexist
immun
limit
efficaci
treatment
induct
antivir
respons
immunotherapi
may
similar
consequ
singl
viru
serotyp
use
repeat
treatment
preexist
induc
immun
could
lead
clearanc
viral
vector
andor
aavtransduc
cell
final
gene
deliveri
aav
report
induc
immun
respons
encod
protein
even
use
endogen
gene
erythropoietin
epo
macaqu
receiv
epoencod
aav
intramuscularli
develop
sever
autoimmun
protein
nonhuman
primat
treat
aav
vector
express
antibodi
antibodylik
protein
titer
drop
rapidli
anim
one
reason
possibl
induc
antiidiotyp
antibodi
requir
immun
suppress
obtain
sustain
express
studi
indic
primat
may
prone
develop
robust
cell
respons
aavencod
protein
compar
mice
summari
risk
insert
mutagenesi
genotox
longlast
express
without
control
case
advers
event
variou
potenti
issu
regard
immunogen
associ
viral
vector
may
limit
efficaci
emphas
high
demand
vector
passiv
immunotherapi
dna
mrna
offer
viabl
option
meet
demand
review
follow
section
cellular
machineri
use
mrna
transient
carrier
genet
inform
synthesi
protein
base
fundament
biolog
concept
administ
exogen
mrna
repres
altern
dnamedi
protein
deliveri
vitro
vivo
use
mrna
instead
dna
therapeut
substanc
attract
due
absent
risk
insert
mutagenesi
moreov
effici
express
even
obtain
nondivid
cell
sinc
mrna
requir
nuclear
phase
activ
compar
deliveri
protein
peptid
mrna
may
prolong
avail
effector
molecul
howev
much
dna
contrast
latter
mrna
therapi
therefor
cope
short
halflif
vivo
exogen
deliv
mrna
instanc
indic
mrnamedi
vegf
express
myocardium
return
baselin
within
h
may
therapeut
disadvantag
variou
instanc
consid
advantag
safeti
perspect
particularli
case
advers
event
mrna
first
employ
express
protein
interest
earli
rna
prepar
microinject
xenopu
oocyt
synthesi
encod
protein
demonstr
group
inder
verma
present
reliabl
method
effici
introduc
rna
varieti
cell
use
cation
lipid
almost
time
mrnamedi
protein
express
vivo
demonstr
direct
inject
mous
muscl
much
earli
work
potenti
therapeut
use
mrna
focus
develop
activ
vaccin
approach
part
sinc
low
amount
antigen
suffic
due
amplifi
natur
immun
respons
subcutan
inject
liposomeencapsul
antigenencod
mrna
first
exampl
elicit
antigenspecif
ctl
respons
mice
gene
gun
deliveri
mrna
mous
epidermi
provid
first
evid
antigenspecif
antibodi
respons
addit
mrna
turn
potent
mean
load
dendrit
cell
antigen
convert
tailor
antigenpres
cell
vitro
vivo
later
new
vaccin
protocol
introduc
elicit
complet
adapt
immun
respons
consist
antigenspecif
antibodi
cell
lytic
activ
without
requir
transfect
reagent
special
equip
heterolog
boost
retrospect
view
event
mark
start
point
commerci
develop
mrna
vaccin
minim
structur
mrna
contain
proteinencod
open
read
frame
orf
flank
two
element
essenti
function
eukaryot
mrna
cap
residu
bound
rna
via
triphosph
bond
except
histon
mrna
poli
tail
synthet
mrna
transcrib
vitro
plasmid
dna
templat
contain
least
bacteriophag
promot
orf
uniqu
restrict
site
linear
plasmid
ensur
defin
termin
transcript
typic
templat
also
contain
poli
sequenc
transcrib
poli
altern
poli
tail
gener
enzymat
vitro
polyadenyl
transcrib
rna
cap
may
incorpor
transcript
transcript
includ
dinucleotid
structur
homolog
endogen
cap
structur
transcript
reaction
differ
option
deriv
ivt
mrna
summar
fig
variou
element
mrna
molecul
contribut
level
durat
express
encod
protein
cap
structur
requir
effici
translat
stabil
mrna
toward
exonucleolyt
decay
variou
structur
repeatedli
use
ivt
mrna
fig
basic
cap
analog
incorpor
orient
rna
bacteriophag
rna
polymeras
howev
revers
incorpor
cap
analog
result
mrna
molecul
lack
methyl
cap
recogn
translat
machineri
substitut
hydroxyl
group
posit
methoxi
group
prevent
revers
incorpor
cap
analog
inhibit
elong
dinucleotid
therefor
call
antirevers
cap
analog
arca
arcacap
mrna
reveal
increas
well
prolong
protein
express
cultur
cell
enhanc
report
protein
express
mous
dendrit
cell
optim
cap
structur
modif
introduc
within
triphosph
linkag
inhibit
decap
substitut
nonbridg
oxygen
moieti
arca
sulfur
result
dinucleotid
maintain
recognit
translat
machineri
protein
express
mrna
cap
extend
cell
immatur
dc
matur
dc
enzymat
cap
repres
altern
cotranscript
approach
avoid
cap
arca
end
mrna
transcrib
without
cap
analog
subsequ
cap
use
vaccinia
viru
cap
complex
complex
triphosphatas
guanylyltransferas
methyltransferas
activ
add
natur
cap
rna
molecul
structur
convert
group
omethyl
ribos
capproxim
nucleotid
use
vaccinia
viru
harbor
omethylribos
subsequ
nucleotid
structur
typic
eukaryot
mrna
recogn
less
cytosol
rna
sensor
innat
immun
system
therebi
render
mrna
less
immunostimulatori
instanc
rigi
activ
mrna
bind
mrna
tightli
molecul
sensormedi
immun
stimul
may
turn
neg
impact
mrna
translat
interest
note
sinc
recent
new
cap
analog
cleancap
avail
enabl
cotranscript
incorpor
structur
ivt
mrna
like
cap
structur
detail
poli
tail
influenc
translat
stabil
mrna
numer
studi
demonstr
posit
effect
poli
tail
correl
effect
length
element
detail
observ
remark
variabl
major
studi
indic
enhanc
translat
extend
poli
length
approxim
nucleotid
tail
extens
use
enzymat
polyadenyl
howev
effect
mostli
moder
reach
maximum
increas
one
particular
set
contrast
anoth
studi
report
optimum
approxim
nucleotid
protein
express
declin
increas
poli
length
addit
poli
length
one
report
suggest
posit
role
use
type
ii
restrict
enzym
dna
templat
linear
obtain
free
poli
end
rather
one
extend
unrel
nucleotid
element
affect
mrna
translat
andor
halflif
untransl
region
utr
sequenc
flank
fig
schemat
represent
differ
cap
structur
typic
cap
eukaryot
mrna
guanosin
methyl
posit
link
first
nucleotid
mrna
unusu
triphosph
bridg
depend
degre
methyl
first
two
base
mrna
full
termin
structur
refer
analog
trinucleotid
introduc
structur
ivt
indic
blue
b
plain
analog
orang
incorpor
two
orient
ivt
c
invers
orient
avoid
use
antirevers
cap
analog
arca
highlight
orang
analog
character
presenc
methoxi
group
either
g
improv
resist
decap
phosphorothio
posit
bridg
arca
orf
sequenc
transact
regulatori
rnabind
protein
rbp
interact
distinct
rna
sequenc
element
therebi
affect
ribosom
recruit
transit
instanc
globin
duplic
globin
tobacco
etch
viru
structur
human
heat
shock
protein
enhanc
mrna
translat
mammalian
cell
accord
recent
survey
combinatori
utr
librari
sequenc
appear
critic
protein
express
contrast
seem
key
driver
mrna
halflif
exemplifi
stabil
effect
globin
well
duplic
globin
codon
usag
orf
sequenc
also
affect
translat
efficaci
mani
speci
although
human
codon
usag
bia
correl
trna
level
gene
express
still
increas
protein
express
mrna
upon
codon
usag
optim
report
instanc
codon
usag
adapt
gag
improv
protein
yield
mrna
approxim
human
lymphocyt
cell
line
pronounc
increas
protein
express
result
codon
optim
report
upon
transfect
mrna
encod
angiotensinconvert
enzym
cell
howev
altern
direct
effect
codon
usag
enhanc
may
indirect
result
use
modifi
nucleotid
content
alter
codon
optim
furthermor
code
sequenc
engin
exploit
advanc
concept
like
codon
optim
may
prove
valuabl
design
therapeut
mrna
high
efficaci
accord
recent
insight
codon
usag
may
also
affect
fidel
translat
stabil
transcript
addit
orf
well
utr
sequenc
effect
immunostimul
thu
translat
activ
initi
research
appli
mrna
contain
four
unmodifi
base
u
c
g
context
instanc
urich
sequenc
well
sever
rna
structur
featur
describ
immunostimulatori
due
interact
variou
rna
sensor
tolllik
receptor
tlr
rigi
protein
kinas
r
pkr
consequ
develop
mrna
therapi
hamper
immunogen
vitro
transcrib
mrna
consider
mrna
therapeut
purpos
gain
momentum
find
incorpor
modifi
base
vitro
transcrib
mrna
reduc
immunostimul
prepar
variou
modifi
base
found
natur
rna
suppress
recognit
tlr
vitro
among
particularli
pseudouridin
increas
translat
stabil
mrna
addit
effect
tlr
bind
replac
uridin
pseudouridin
affect
bind
activ
sensor
pkr
synthetas
contribut
higher
longer
protein
express
howev
effect
mrna
modif
translat
immunostimul
result
protein
express
appear
variabl
instanc
depend
type
target
cell
vitro
test
variou
modif
combin
thereof
reveal
decreas
protein
yield
context
depend
manner
reduc
immunostimul
macrophag
found
vitro
pseudouridin
modif
mrna
reduc
immunostimul
increas
level
durat
protein
express
intraven
iv
intraperiton
administr
formul
mrna
mice
contrast
anoth
studi
system
administr
nanoparticlecomplex
mrna
conclud
neither
immunostimul
protein
express
benefit
pseudouridin
modif
intraderm
intramuscular
inject
formul
mrna
pseudouridin
substanti
enhanc
express
line
differ
studi
appli
lipid
nanoparticl
lnp
formul
mrna
intraderm
found
replac
uridin
result
much
increas
longer
last
protein
express
notabl
recent
studi
reveal
also
endogen
eukaryot
mrna
harbor
variou
modifi
nucleotid
howev
total
level
modif
rather
low
strong
contrast
usual
replac
unmodifi
nucleotid
ivt
mrna
moreov
heavi
nucleotid
modif
appear
interfer
function
translationenhanc
rna
element
utr
intern
ribosom
entri
site
ires
time
modifi
nucleotid
introduc
minim
immunostimul
ivt
mrna
import
stringent
purif
prepar
recogn
chromatograph
purif
particularli
hplc
separ
mrna
accord
size
therebi
remov
smaller
larger
byproduct
abort
transcript
mrna
trace
nonlinear
dna
templat
doublestrand
rna
fig
purif
enhanc
protein
yield
probabl
enrich
function
transcript
deplet
contamin
caus
detriment
immunostimul
latter
corrobor
find
stringent
purif
reduc
benefici
effect
chemic
modif
even
made
dispens
particularli
combin
specif
sequenceengin
mrna
importantli
specif
mrna
formul
anoth
layer
influenc
activ
innat
immun
system
mask
mrna
recognit
sensor
particularli
tlr
exampl
immun
respons
mrna
administr
central
nervou
system
effect
suppress
use
nanomicel
formul
compar
nake
mrna
vivo
administr
mrna
proven
feasibl
concept
use
mrna
basi
therapeut
pursu
almost
immedi
first
report
therapeut
effect
exogen
mrna
alreadi
publish
describ
temporari
revers
diabet
insipidu
rat
intrahypothalam
inject
vasopressin
mrna
thereaft
took
almost
two
decad
studi
start
demonstr
broad
potenti
mrnabas
protein
therapi
meanwhil
plethora
public
huge
varieti
indic
compris
anemia
hemophilia
myocardi
infarct
cancer
lung
diseas
surfact
b
defici
asthma
metabol
disord
fibrosi
skelet
degener
tendon
impair
neurolog
disord
sensori
nerv
dysfunct
friedreich
ataxia
alzheim
diseas
wherea
evid
therapeut
potenti
mrna
mostli
restrict
mous
model
first
data
swine
indic
mrnabas
protein
therapi
feasibl
also
larg
anim
view
variou
indic
hardli
surpris
divers
goe
along
differ
rout
administr
variou
formul
studi
look
local
administr
use
uncomplex
thu
unprotect
mrna
major
investig
built
lipidbas
formul
clear
tendenc
applic
lnp
group
purifi
ivt
mrna
vivo
administr
simpli
precipit
mrna
use
commerci
purif
kit
research
appli
hplc
purif
respect
mrna
vast
major
studi
use
long
poli
tail
least
nucleotid
likewis
clear
preval
chemic
modifi
mrna
although
variou
exampl
suggest
mandatori
mrna
harbor
andor
pseudouridin
initi
appear
trend
toward
use
present
regard
cap
structur
almost
earli
studi
cotranscript
gener
mrna
use
arca
howev
sinc
year
research
group
prefer
appli
mrna
initi
attempt
appli
mrna
passiv
immunotherapi
focus
cellular
approach
variou
reason
adopt
transfer
ctl
equip
either
addit
tcr
car
shown
great
promis
cancer
viral
infect
contrast
typic
scenario
antibodi
therapi
receptor
express
usual
requir
much
lower
protein
level
furthermor
cell
load
receptorencod
nucleic
acid
dna
mrna
ex
vivo
henc
passiv
cellular
immunotherapi
requir
sophist
highli
effici
formul
vivo
deliveri
build
armamentarium
cell
transfect
method
previou
work
activ
cellular
vaccin
antigenpres
cell
transfect
antigenencod
mrna
reveal
electropor
easi
effici
mean
load
cell
comparison
passiv
cell
puls
lipofect
demonstr
electropor
also
effici
transfect
lymphocyt
rna
electropor
effici
without
elicit
critic
toxic
onset
transgen
express
rapid
last
day
receptor
transfer
cell
mrna
electropor
well
establish
mani
year
moreov
gmpcompliant
protocol
manufactur
receptorexpress
retent
time
cell
prepar
via
mrna
electropor
avail
today
electropor
human
lymphocyt
variou
antigenspecif
tcr
redirect
recogn
cancer
cell
mhcdepend
manner
vitro
mrnamedi
tcr
express
confer
vitro
cytotox
cell
least
h
lytic
efficaci
cell
compar
retrovir
transduc
lymphocyt
likewis
transfect
carencod
mrna
gener
cell
lytic
activ
vitro
use
optim
ivt
mrna
car
surfac
express
cytotox
function
detect
day
avoid
mani
manipul
step
possibl
gener
cell
adopt
transfer
demonstr
human
peripher
blood
lymphocyt
instead
purifi
lymphocyt
could
use
well
elicit
strong
cytotox
vitro
upon
electropor
car
mrna
current
car
approach
deploy
cell
howev
lymphocyt
attract
target
well
due
antitumor
effector
function
mhc
restrict
requir
costimul
accordingli
mrnamedi
tcr
car
express
cell
investig
recent
shown
kill
target
cell
antigenspecif
manner
best
knowledg
far
one
studi
start
systemat
analyz
role
differ
mrna
element
receptor
express
cell
end
group
carl
june
built
previou
find
dendrit
cell
reveal
superior
duplic
globin
singl
copi
element
long
nt
short
nt
poli
tail
respect
receptor
express
enhanc
express
compar
tandem
repeat
globin
also
benefici
effect
particularli
combin
long
poli
contrast
vegf
translat
enhanc
element
even
detriment
consequ
author
specul
may
due
reduc
cap
efficaci
provid
data
corrobor
hypothesi
howev
demonstr
import
role
cap
structur
cotranscript
use
arca
enzymat
gener
structur
equival
outperform
basic
cap
analog
well
enzymat
besid
express
level
cap
also
appear
effect
persist
express
modif
orf
sequenc
remov
intern
orf
effect
receptor
product
lymphocyt
transfect
tcror
carencod
mrna
prove
function
also
vivo
robust
antitumor
effect
observ
variou
preclin
model
mrnaspecif
sinc
mocktransfect
cell
littl
unspecif
impact
although
mrnamedi
receptor
express
transient
singl
inject
car
cell
suffici
prolong
surviv
mice
use
peripher
blood
lymphocyt
instead
purifi
cell
car
mrna
transfect
see
also
enabl
strong
antitumor
respons
vivo
although
cell
could
persist
longterm
vitro
recent
shown
mrna
use
drive
receptor
express
support
gener
cell
adopt
immunotherapi
express
chimer
membran
protein
cell
could
effici
stimul
expand
vitro
transfect
mrna
bite
cell
mediat
sustain
reduct
tumor
burden
upon
intraperiton
inject
base
encourag
preclin
data
adopt
cell
therapi
use
mrna
alreadi
subject
first
clinic
test
phase
trial
solid
tumor
address
safeti
feasibl
use
cell
car
transfect
lymphocyt
migrat
tumor
site
iv
inject
addit
studi
appear
provid
initi
evid
antitumor
activ
due
transient
natur
mrna
express
subject
receiv
repeat
infus
cell
led
anaphylact
respons
one
patient
develop
antibodi
specif
scfv
domain
car
howev
could
consequ
murin
origin
domain
anoth
trial
mrnatransfect
car
cell
inject
intratumor
metastat
breast
cancer
patient
treatment
well
toler
elicit
inflammatori
respons
within
tumor
discuss
use
viral
vector
adopt
cell
therapi
potenti
safeti
issu
variou
studi
author
ascrib
toxic
particularli
persist
receptorexpress
cell
regard
concern
mrnamedi
tcr
car
express
offer
least
two
advantag
first
mrna
integr
cell
genom
thu
exclud
genotox
second
due
transient
natur
potenti
toxic
accompani
treatment
temporari
well
howev
increas
level
safeti
substanti
drawback
appar
clinic
efficaci
correl
longterm
persist
receptorengin
cell
consequ
mrnatransfect
cell
expect
limit
antitumor
activ
rapidli
declin
receptor
express
substanti
mrna
translat
last
day
translat
efficaci
receptor
level
cell
surfac
sever
day
importantli
clinic
studi
demonstr
iv
infus
lymphocyt
reach
tumor
site
day
administr
consequ
intratumor
intraarteri
administr
suggest
counteract
delay
cell
arriv
problem
transienc
mrna
enhanc
wellknown
ligandinduc
receptor
intern
upon
target
recognit
tcr
well
car
rapidli
intern
mechan
import
proper
signal
transduct
explain
lentivir
vector
gener
robust
treatment
effect
mrna
mrna
transfect
give
rise
high
receptor
express
equal
lentivir
vector
howev
mrna
similarli
effect
first
hour
electropor
later
contact
target
cell
strongli
downregul
receptor
cell
surfac
lentivir
express
remain
constant
comparison
singl
transfer
cell
retrovir
car
express
mrnaencod
receptor
requir
three
consecut
lymphocyt
infus
obtain
compar
antitumor
effect
observ
consider
may
put
perspect
least
part
find
transfer
cell
becom
toler
rather
rapidli
therebi
lose
abil
function
tumor
microenviron
thu
frequent
inject
cell
may
desir
even
viral
vector
transduc
cell
notabl
mrna
also
consid
use
set
requir
longterm
express
therapeut
efficaci
preclud
repeat
cell
administr
greater
safeti
mrnatransfect
cell
may
make
initi
test
novel
antigen
receptor
unknown
ontargetofftissu
toxic
less
hazard
passiv
immun
antibodi
often
requir
consider
amount
polypeptid
obtain
therapeut
activ
concentr
system
administr
pose
substanti
challeng
broad
applic
nucleic
acid
mediat
passiv
immun
strategi
thu
compar
first
attempt
regard
vivo
protein
express
mrna
optim
ivt
mrna
enhanc
extend
express
prerequisit
mani
mrnabas
passiv
immunotherapi
review
great
progress
toward
goal
made
last
almost
three
decad
anoth
potenti
hurdl
passiv
mrna
immun
relat
deliveri
obtain
high
level
vivo
antibodi
express
mrna
target
mani
produc
cell
possibl
turn
transfect
high
effici
end
mrna
prone
degrad
rnase
also
protect
ubiquit
nucleas
appropri
manner
moreov
viabl
mrna
complex
reagent
need
well
toler
notabl
variou
commerci
transfect
reagent
use
formul
mrna
suffic
research
purpos
among
transit
repeatedli
use
vivo
studi
respect
potenti
therapeut
applic
class
lipid
nanoparticl
lnp
becam
wide
deploy
mean
complex
iv
deliveri
lnp
mainli
rout
liver
basi
apolipoprotein
e
apo
depend
mechan
howev
nanoparticl
demonstr
also
applic
intramuscular
subcutan
administr
advanc
mrna
formul
technolog
led
coupl
recent
intrigu
studi
passiv
immun
mrna
fig
group
drew
weissman
describ
success
passiv
mrna
immun
prophylaxi
viral
infect
stadler
et
al
demonstr
applic
mrnamedi
antibodi
express
cancer
immunotherapi
feasibl
use
mrna
indic
confirm
thran
et
al
appli
differ
mrnaencod
antibodi
format
divers
biolog
threat
virus
toxin
tumor
final
sabni
colleagu
present
first
antibodi
express
data
nonhuman
primat
nhp
public
deal
develop
novel
lnp
formul
schemat
illustr
mrnamedi
passiv
antibodi
immunotherapi
vivo
administr
mrna
usual
formul
nanoparticl
instanc
administ
iv
inject
mani
formul
liver
main
target
organ
upon
uptak
nanoparticl
hepatocyt
releas
mrna
cytosol
translat
antibodi
typic
secret
circul
final
bind
cognat
antigen
mrna
design
formul
fundament
design
antibodyencod
mrna
reveal
common
featur
sever
differ
tabl
among
latter
exclus
use
chemic
unmodifi
nucleotid
thran
et
al
previou
public
group
may
promin
one
sinc
contrast
report
differ
much
divers
among
studi
henc
provid
unequivoc
guidanc
futur
work
least
common
may
taken
recommend
although
obvious
mandatori
mrna
structur
clearli
prefer
addit
mrna
harbor
poli
tail
use
bipartit
poli
element
group
may
owe
experi
mainten
long
poli
vector
sequenc
challeng
strongli
depend
bacteri
strain
beyond
common
rna
element
public
suggest
mrna
subject
optim
exploit
full
potenti
antibodi
express
howev
differ
strategi
appear
applic
littl
known
interchang
individu
element
final
chromatograph
purif
ivt
mrna
appear
gener
recommend
well
tabl
whether
pardi
et
al
actual
use
fplc
state
throughout
report
instead
hplc
appli
group
fulli
clear
sinc
refer
earlier
public
describ
use
hplc
pardi
et
al
encod
wellknown
broadli
neutral
antibodi
end
heavi
light
chain
full
igg
antibodi
repres
separ
mrna
molecul
deliveri
heavi
light
chain
mrna
mix
molar
ratio
likewis
thran
et
al
use
separ
mrna
encod
heavi
light
chain
variou
full
igg
antibodi
titrat
heavi
light
chain
mrna
found
molar
ratio
approxim
optim
codeliveri
neither
report
provid
rational
encod
chain
separ
molecul
principl
bicistron
construct
separ
heavi
light
chain
ire
sequenc
mrna
polypeptid
sequenc
heavi
light
chain
would
lead
separ
antibodi
chain
ribosom
skip
could
use
pardi
et
al
observ
modifi
nucleotid
hamper
function
ire
element
may
affect
select
sabni
et
al
also
work
full
igg
antibodi
direct
influenza
provid
detail
heavi
light
chain
repres
contrast
stadler
et
al
chose
bite
antibodi
direct
tcrassoci
one
three
differ
tumorassoci
antigen
taa
display
bite
fab
scfv
scfv
molecul
focus
latter
format
find
singlechain
antibodi
complement
thran
et
al
whose
work
cover
singl
domainderiv
vna
addit
igg
antibodi
iv
administr
antibodyencod
mrna
group
ugur
sahin
use
lnp
formul
howev
may
differ
composit
tabl
latter
team
exploit
transit
switch
rout
administr
intraperiton
previou
studi
lnp
nanoparticl
shown
mainli
target
liver
upon
iv
inject
drew
weissman
group
administ
mrna
vivo
studi
correspond
dose
mgkg
due
differ
mous
weight
among
experi
antibodi
serum
titer
h
administr
earliest
time
analysi
rang
approxim
variou
mous
strain
obvious
slight
differ
dosag
well
respect
strain
contribut
vari
peak
level
notabl
increas
administ
mrna
dose
step
two
enhanc
serum
titer
twofold
step
moreov
mrna
lnp
gener
higher
serum
titer
recombin
protein
kinet
antibodi
serum
titer
reveal
acceler
declin
week
balbc
mice
kinet
nsg
mice
appear
basic
sinc
level
week
singl
administr
larg
balbc
time
observ
kinet
may
also
explain
weekli
inject
mrnalnp
nsg
mice
show
addit
effect
serum
titer
time
analys
sinc
measur
conduct
day
treatment
antibodi
preced
inject
probabl
drop
background
level
within
period
observ
balbc
anim
acceler
declin
protein
titer
day
often
indic
induct
antidrug
antibodi
ada
respons
likelihood
respons
may
particularli
high
report
experi
sinc
author
express
human
antibodi
mice
emerg
ada
fulli
rule
anim
analyz
accordingli
howev
appar
similar
kinet
immunocompromis
nsg
mice
unabl
develop
ada
suggest
differ
explan
pharmacokinet
possibl
mrna
continu
express
antibodi
day
would
inevit
lead
seemingli
extend
antibodi
serum
halflif
period
express
ceas
actual
shorter
antibodi
halflif
becom
evid
could
also
easili
explain
serum
profil
repeat
treatment
nsg
mice
remain
hypothet
due
lack
respect
analys
stadler
et
al
first
character
mrna
vitro
demonstr
express
secret
function
antibodi
pbmcmediat
kill
assay
mrnaderiv
bite
antibodi
target
ctl
tumor
cell
via
bind
pbmc
cognat
taa
tumor
cell
therebi
induc
cell
activ
tumor
cell
lysi
antibodi
equal
potent
correspond
recombin
protein
immunodefici
nsg
mice
antibodi
plasma
level
peak
within
h
rapidli
declin
within
next
h
subsequ
decreas
bite
titer
becam
much
slower
author
provid
explan
strike
kinet
pharmacokinet
analysi
nontumorbear
mice
could
elucid
whether
initi
kinet
reflect
trap
antibodi
engraft
tumor
satur
bind
site
bite
plasma
level
background
day
accord
sustain
ex
vivo
cytotox
plasma
mrnatreat
mice
contrast
antibodi
plasma
kinet
cytotox
show
steadi
slow
declin
observ
period
mrna
alreadi
suffici
obtain
strong
plasma
activ
ex
vivo
kill
assay
mrna
approx
mgkg
compar
recombin
antibodi
respect
peak
plasma
concentr
rang
nsg
mice
oppos
modifi
hplcpurifi
mrna
antibodi
plasma
level
almost
undetect
mrna
prepar
without
modif
chromatograph
purif
plasma
titer
declin
much
faster
recombin
protein
compar
mrna
therebi
demonstr
substanti
impact
mrna
bite
pharmacokinet
consequ
mrna
abl
maintain
sustain
cytotox
activ
plasma
weekli
administr
variou
mrnaencod
antibodi
thran
et
al
includ
use
drew
weissman
work
howev
analys
limit
vitro
character
prevent
direct
comparison
studi
observ
bite
igg
vna
antibodi
produc
mrna
vitro
reveal
potenc
compar
respect
recombin
protein
iv
administr
unmodifi
mrna
approx
mgkg
gave
rise
antibodi
serum
titer
ml
immunocompet
mice
contrast
strongli
find
stadler
et
al
found
unmodifi
mrna
basic
inact
differ
purif
mrna
design
may
respons
strike
discrep
similar
weissman
work
thran
colleagu
observ
disproportion
increas
antibodi
serum
titer
elev
mrna
dose
onset
antibodi
express
rather
rapid
alreadi
substanti
h
inject
reach
peak
level
approxim
h
confirm
find
mrnamedi
protein
therapi
show
mrna
start
accumul
hepatocyt
within
minut
administr
lead
substanti
protein
level
within
coupl
hour
serum
halflif
igg
antibodi
appear
rang
week
thu
slightli
longer
compar
pardi
et
al
latter
studi
one
two
igg
show
acceler
declin
week
howev
approxim
half
anim
expedit
clearanc
could
assign
develop
ada
respons
mrnaencod
antibodi
importantli
respons
antibodydepend
intim
link
use
mrna
expect
vna
reveal
much
shorter
serum
halflif
day
compar
publish
kinet
data
recombin
vna
mrna
appear
contribut
extend
antibodi
avail
first
day
administr
observ
biteexpress
mrna
ugur
sahin
group
howev
lack
headtohead
comparison
hamper
detail
analysi
previou
vivo
studi
mrnamedi
antibodi
express
limit
mice
sabni
et
al
present
express
result
nhp
use
proprietari
lnp
formul
mgkg
dose
mrna
gave
rise
antibodi
serum
titer
h
iv
administr
least
lower
end
rang
efficaci
observ
mous
studi
howev
data
differ
protein
suggest
efficaci
formul
may
slightli
lower
nhp
mous
wherea
mg
kg
dose
induc
protein
level
approxim
mice
mgkg
dose
gener
protein
titer
ngml
nhp
mous
studi
mrnaencod
antibodi
investig
therapeut
efficaci
pardi
et
al
use
two
differ
human
mous
model
demonstr
mrnaderiv
protect
challeng
mrna
encod
report
protein
util
control
mrnalnp
administ
h
prior
challeng
one
two
isol
author
first
model
mrna
dose
mgkg
ineffect
mgkg
alreadi
reduc
viral
rna
copi
plasma
undetect
level
assess
quantit
realtim
polymeras
chain
reaction
qrtpcr
latter
dose
well
mgkg
dose
typic
use
prophylact
immun
recombin
antibodi
human
mice
reach
therapeut
concentr
howev
author
titrat
dose
recombin
use
mgkg
dose
control
suffici
complet
erad
viral
rna
copi
plasma
mrna
efficaci
could
also
demonstr
second
mous
challeng
model
show
vivo
efficaci
mrnamedi
bite
express
stadler
et
al
implant
tumor
cell
subcutan
immunodefici
nsg
mice
week
mrna
treatment
human
pbmc
engraft
anim
bite
mrna
approx
mg
kg
given
three
time
interv
week
could
elimin
tumor
entir
contrast
tumor
progress
control
anim
receiv
mrna
encod
report
protein
recombin
bite
requir
three
inject
per
week
total
ten
inject
obtain
compar
antitumor
effect
bite
mrna
need
frequent
administr
corrobor
previou
find
mrna
substanti
improv
antibodi
plasma
halflif
due
divers
antibodi
includ
studi
thran
et
al
util
variou
diseas
model
demonstr
therapeut
efficaci
contrast
studi
author
appli
mrna
encod
irrelev
antibodi
instead
report
protein
control
dose
approx
mgkg
antibodi
mrna
could
protect
mice
challeng
either
rabi
viru
botulinum
toxin
intox
model
mrna
proven
equal
protect
recombin
antibodi
howev
mice
receiv
approxim
mgkg
recombin
vna
compar
approxim
mgkg
mrna
base
protein
express
level
mrna
dose
titrat
lower
dose
mgkg
may
still
confer
full
protect
remain
hypothet
sinc
author
conduct
mrna
dose
titrat
challeng
model
notabl
mrna
effect
prea
well
postexposur
set
latter
import
indic
passiv
immun
confirm
aforement
rapid
onset
antibodi
express
postexposur
scenario
botulinum
toxin
requir
rapid
avail
neutral
antibodi
wherea
recombin
protein
act
immedi
administr
mrna
need
time
provid
antibodi
henc
may
well
instanc
higher
dose
mrna
protein
requir
obtain
peak
level
reach
meaning
titer
time
manner
model
thran
et
al
evalu
mrna
approach
respect
antitumor
efficaci
use
dissemin
tumor
model
rituximab
show
effici
tumor
growth
control
inject
approx
mgkg
rituximab
mrna
twice
week
higher
dose
approx
mgkg
recombin
rituximab
less
potent
find
reminisc
result
drew
weissman
group
contrast
ugur
sahin
colleagu
requir
similar
dose
mrna
recombin
protein
less
frequent
dose
mrna
obtain
equival
therapeut
effect
notabl
differ
among
studi
may
relat
use
igg
antibodi
one
hand
scfv
protein
hand
moreov
irrelev
antibodi
control
use
thran
et
al
appear
slight
unspecif
antitumor
effect
may
contribut
superior
mrna
compar
recombin
protein
regard
dose
amongst
explan
potenti
unspecif
effect
may
due
mrnalnpindepend
respons
repeat
treatment
may
consequ
weak
transient
cytokin
respons
observ
mrnalnp
administr
howev
phenomenon
investig
line
previou
report
pardi
et
al
confirm
import
highli
purifi
ivt
mrna
combin
lnp
modif
plu
chromatograph
purif
suffici
avoid
cytokin
releas
innat
immun
activ
analysi
howev
author
deploy
mrna
encod
differ
protein
antibodi
use
vivo
express
efficaci
experi
toler
mrnalnp
also
address
repeat
mrna
treatment
translat
mrna
compromis
time
analysi
conduct
immunodefici
nsg
mice
overcom
caveat
author
complement
studi
repetit
treatment
immun
compet
balbc
mice
end
switch
endogen
protein
sinc
human
may
recogn
foreign
thu
elicit
immun
respons
mrna
inject
lose
efficaci
time
howev
author
also
chang
formul
transit
instead
lnp
well
rout
administr
intraperiton
instead
iv
compar
use
mrna
henc
evid
immun
silenc
overal
toler
mrna
lnp
circumstanti
yet
stadler
et
al
observ
liver
toxic
upon
treatment
mrna
transit
accord
liver
enzym
analys
moreov
bite
mrna
administr
elev
murin
cytokin
background
plasma
likewis
analysi
system
human
cytokin
releas
engraft
pbmc
show
unspecif
cell
activ
oppos
modifi
hplcpurifi
mrna
prepar
without
nucleotid
modif
chromatograph
purif
induc
detect
level
murin
cytokin
similar
weissman
group
author
also
assess
toler
formul
mrna
repeat
inject
administr
lose
efficaci
time
correspond
weissman
experi
immunodefici
nsg
mice
use
use
chemic
unmodifi
mrna
formul
lnp
thran
et
al
observ
liver
toxic
histopatholog
analys
anim
develop
ada
respons
depend
encod
antibodi
thu
intrins
consequ
treatment
mrnalnp
addit
treatment
appear
elicit
transient
weak
cytokin
releas
howev
neither
suppress
antibodi
express
induc
advers
effect
sinc
ampl
differ
among
studi
mrnamedi
antibodi
express
detail
analys
issu
role
mrna
lnp
andor
encod
antibodyprotein
cytokin
induct
remain
elus
earlier
studi
erythropoietin
show
absenc
appreci
immunostimul
suggest
use
chemic
unmodifi
instead
modifi
mrna
decis
paramet
quit
vivo
studi
provid
compel
evid
principl
feasibl
mrnabas
immunotherapi
discuss
challeng
open
question
regard
adopt
cell
transfer
less
relat
mrna
formul
transfect
fundament
charact
contrast
ex
vivo
load
cell
mrnamedi
antibodi
express
strongli
affect
bodi
size
thu
convinc
efficaci
data
divers
small
rodent
model
translat
larger
anim
final
human
still
demonstr
first
data
suggest
substanti
express
obtain
small
nhp
howev
util
lnp
appear
lose
efficaci
switch
mous
nhp
henc
develop
human
therapi
may
perhap
requir
advanc
mrna
technolog
well
primatespecif
formul
improv
efficaci
addit
toler
formul
analyz
depth
futur
instanc
repeat
dose
nanoparticl
induc
complement
activationrel
pseudoallergi
carpa
howev
principl
counteract
optim
toward
better
biocompat
case
lnp
fast
degrad
shown
particularli
import
antibodi
cancer
treatment
initi
develop
iv
administr
trend
toward
subcutan
inject
today
instanc
rituximab
initi
formul
iv
infus
typic
administ
period
h
treatment
schedul
pose
substanti
burden
patient
well
healthcar
system
thu
formul
reduc
time
requir
resourc
would
advantag
meet
goal
subcutan
administr
antibodi
solut
concentr
sinc
volum
still
larg
subcutan
inject
rituximab
coformul
human
hyaluronidas
limit
swell
associ
pain
increas
dispers
absorpt
coadminist
substanc
median
administr
time
rituximab
use
subcutan
rout
min
consequ
antibodi
immunotherapi
mrna
requir
competit
efficaci
cost
also
rout
administr
becom
viabl
altern
recombin
protein
although
rout
iv
shown
possibl
mrna
still
open
question
address
futur
studi
advantag
use
mrna
antibodi
immunotherapi
compar
dna
may
primarili
safeti
aspect
concern
recombin
protein
variou
point
matter
review
mrna
provid
benefit
pharmacokinet
shortliv
antibodi
scfv
bi
scfv
vna
use
moreov
solv
challeng
antibodi
cocktail
may
easier
use
mrna
differ
mrna
sequenc
much
similar
respect
physicochem
characterist
differ
protein
henc
produc
cocktail
may
less
demand
mrna
compar
protein
howev
codeliveri
thu
coexpress
implic
risk
antibodi
chimer
thu
requir
specif
solut
knobintohol
concept
last
least
protein
difficult
deliv
directli
cell
membran
mrnamedi
protein
express
make
larg
number
potenti
intracellular
target
access
antibodi
immunotherapi
particularli
singlechain
singledomain
format
amen
function
express
cytosol
thu
suit
intrabodi
sinc
less
depend
disulfid
bond
format
valu
target
intracellular
protein
alreadi
demonstr
variou
studi
bispecif
scfv
could
restor
function
mutant
colon
cancer
cell
trap
er
via
intrabodi
reduc
hiv
cell
entri
support
potenti
intrabodi
therapeut
also
come
work
field
oncolog
neurodegen
diseas
although
recent
demonstr
even
full
antibodi
deliv
cell
vivo
recogn
fusion
cellpenetr
peptid
cpp
macromolecul
often
trap
endosom
instead
releas
cytoplasm
contrast
nucleic
acid
includ
mrna
effici
transfect
cell
make
ideal
deliveri
intrabodi
howev
lnp
provid
effici
solut
system
deliveri
liver
formul
rout
mrna
tissu
scarc
today
recent
burst
public
success
applic
mrnabas
antibodi
immunotherapi
like
much
follow
near
futur
